Home / Going-concern warnings / GALECTIN THERAPEUTICS INC
Filed 2025-11-14 路 Form 10-Q 路 Accession 0001140361-25-042116 small
Price before filing: $5.53 (2025-11-13 close, split/dividend-adjusted)
Market cap at flag: $352.1M (2025-11-14) 路 Latest: $238.5M (2026-10-16)
| Window | GALT | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +17.7% | +1.3% | +16.4% | 2025-12-15 |
| 90 days | -49.2% | +1.7% | -50.9% | 2026-02-12 |
| 180 days | -59.7% | +11.1% | -70.8% | 2026-05-13 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 4 insiders sold $1.4M (22 sales)
30 days after: 4 insiders sold $2.6M (17 sales)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-09-12 | CALLICUTT JACK W Chief Financial Officer | Sale | 8,706 | $6.44 | $56K | yes | Form 4 |
| 2025-09-12 | LEWIS JOEL President and CEO, Director | Sale | 14,000 | $6.36 | $89K | yes | Form 4 |
| 2025-10-22 | 10X Fund, L.P. (+2 joint filers) 10% owner | Sale | 20,000 | $4.93 | $99K | no | Form 4 |
| 2025-10-22 | 10X Fund, L.P. (+2 joint filers) 10% owner | Sale | 30,000 | $4.94 | $148K | no | Form 4 |
| 2025-11-03 | CALLICUTT JACK W Chief Financial Officer | Sale | 1,300 | $6.01 | $8K | yes | Form 4 |
| 2025-11-03 | CALLICUTT JACK W Chief Financial Officer | Sale | 1,260 | $6.01 | $8K | yes | Form 4 |
| 2025-11-03 | CALLICUTT JACK W Chief Financial Officer | Sale | 1,250 | $6.01 | $8K | yes | Form 4 |
| 2025-11-03 | LEWIS JOEL President and CEO, Director | Sale | 1,300 | $6.01 | $8K | yes | Form 4 |
| 2025-11-04 | CALLICUTT JACK W Chief Financial Officer | Sale | 8,914 | $6.07 | $54K | yes | Form 4 |
| 2025-11-04 | CALLICUTT JACK W Chief Financial Officer | Sale | 8,974 | $6.07 | $54K | yes | Form 4 |
| 2025-11-04 | CALLICUTT JACK W Chief Financial Officer | Sale | 10,741 | $6.07 | $65K | yes | Form 4 |
| 2025-11-04 | LEWIS JOEL President and CEO, Director | Sale | 14,420 | $6.07 | $88K | yes | Form 4 |
| 2025-11-05 | CALLICUTT JACK W Chief Financial Officer | Sale | 200 | $6.00 | $1K | yes | Form 4 |
| 2025-11-05 | LEWIS JOEL President and CEO, Director | Sale | 200 | $6.00 | $1K | yes | Form 4 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Sale | 1,880 | $6.02 | $11K | yes | Form 4 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Sale | 1,675 | $6.03 | $10K | yes | Form 4 |
| 2025-11-10 | CALLICUTT JACK W Chief Financial Officer | Sale | 1,736 | $6.03 | $10K | yes | Form 4 |
| 2025-11-10 | LEWIS JOEL President and CEO, Director | Sale | 1,867 | $6.03 | $11K | yes | Form 4 |
| 2025-11-11 | 10X Fund, L.P. (+2 joint filers) 10% owner | Sale | 40,000 | $5.25 | $210K | no | Form 4 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Sale | 21,867 | $5.47 | $120K | yes | Form 4 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Sale | 41,500 | $5.47 | $227K | yes | Form 4 |
| 2025-11-13 | Jamil Khurram Chief Medical Officer | Sale | 16,250 | $5.47 | $89K | yes | Form 4 |
| 2025-11-14: red flag filed | |||||||
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Sale | 9,586 | $6.03 | $58K | yes | Form 4 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Sale | 19,701 | $6.03 | $119K | yes | Form 4 |
| 2025-11-17 | CALLICUTT JACK W Chief Financial Officer | Sale | 2,323 | $6.03 | $14K | yes | Form 4 |
Showing 25 of 39 transactions.
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-08-16 to 2025-12-14. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"However, substantial doubt about the Company's ability to continue as a going concern exists."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-09-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.